• Neurobell

  Participated · Equity · Jun 2026

  NeuroBell develops LUNA, a battery-powered, WiFi-connected neonatal electroencephalogram (EEG) system that provides bedside, clinical-grade brain monitoring. LUNA features an eight-channel EEG amplifier, 10-20 EEG electrode placement for neonates, a two-button setup to begin recording, and continuous impedance checks. The system offers automated neonatal seizure detection to support quicker identification of seizures and decision-making by NICU staff. NeuroBell says LUNA enables quick setup and recording for NICU teams regardless of size or location and supports continuous monitoring at the bedside. The company is based in Cork, Ireland, and is anticipating FDA clearance in the coming months. NeuroBell raised $5.5 million in a financing led by Elkstone, with participation from Parkview Health and existing investors to support clinical deployment and U.S. market entry.

• CroíValve

  Participated · Series B · Jun 2026

  CroíValve is developing the DUO System, a novel transcatheter heart valve that preserves native anatomy and works in tandem with the tricuspid valve to restore function while avoiding contact with critical right-heart structures. The DUO Adapt System features an adaptive coaptation valve designed to fill larger and complex leaks and has shown early clinical use treating leaks up to 35mm with significant reduction in tricuspid regurgitation. The device is investigational and not for sale in any geography. CroíValve plans to expand its TANDEM II prospective, multicenter study across additional US and EU sites to further evaluate safety and performance, building on 15 patients already treated. The company recently expanded its Series B financing and secured grant funding to support this clinical expansion, and has R&D and operations in Ireland with clinical and regulatory functions in the US.

• Vertigenius

  Participated · Equity · Apr 2026

  Vertigenius develops a wearable head-sensor medical device and platform that enables clinicians to remotely monitor vertigo patients and track treatment progress. The company registered with the FDA and launched in the US in October, where 20 clinics in 11 states have used its device to treat around 3,000 patients. Vertigenius says its platform accelerates clinician workflows, reduces clinic visits, and enables clinics to access additional insurance reimbursement for remote monitoring in the US. The company positions the US as an addressable market of over €3bn with more than 5,000 vestibular clinics and plans to grow its US commercial presence. With a €2.55m raise following a €2.1m round in 2024, Vertigenius will hire across clinical research, product R&D, quality assurance and regulatory affairs while maintaining its Irish headquarters. Vertigenius aims to expand further across Europe and into Asia Pacific over the next five years.

• illumicell AI

  Participated · Seed · Apr 2025

  Illumicell AI builds a portable "lab scanner" and real-time AI platform that analyzes cells and biomarkers in fluid samples within minutes, initially targeting semen diagnostics for male fertility. The company has collected over 400,000 datapoints and generates structured, labeled cell data to enable personalized insights such as lifestyle-linked fertility changes and early decline warnings. Early clinical trials reportedly outperform legacy systems, and the platform is designed to extend beyond semen to fluids like urine and cerebrospinal fluid. The startup plans an FDA submission in 2026 as it advances clinical validation. Founded in 2023 as a Swiss-American company and led by physician and technical co-founders, illumicell AI has been selected by programs including Harvard i-Labs, Creative Destruction Lab, MassChallenge, Techstars, and Keihanna KGAP+. The company raised funding to accelerate development and commercialization of its real-time diagnostics platform.

• FeelTect

  Participated · Equity · Dec 2023

  FeelTect’s core product, Tight Alright, integrates disposable pressure sensors with a reusable transmitter and cloud platform to give clinicians real-time data on sub-bandage pressure during compression therapy. By keeping pressure within therapeutic ranges, the technology aims to shorten healing times and cut overall treatment costs for chronic wounds. After multi-year clinical validation, the company is moving from pilot studies to its first commercial deployment at Thun Hospital in Switzerland. The recent funding will finance a broader commercial roll-out, regulatory expansion into additional markets, and team growth at its Spiddal, Galway base. FeelTect previously secured a similar capital injection in 2023 to fund product finalisation and early market preparation. Investors across the two rounds include Irrus Investments, the Western Development Commission, Halo Business Angel Network, and other individual angels. The company has not yet disclosed revenue or user numbers but positions itself to become a global leader in compression-therapy monitoring.

No current team members are available.